Performance of D-dimer to lymphocyte ratio in predicting the mortality of COVID-19 patients

• Published in: Frontiers in cellular and infection microbiology Vol. 12; p. 1053039
• Main Authors: Peng, Fei, Yi, Qiong, Zhang, Quan, Deng, Jiayi, Li, Cheng, Xu, Min, Wu, Chenfang, Zhong, Yanjun, Wu, Shangjie
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.12.2022
• Subjects: Cellular and Infection Microbiology; COVID-19; COVID-19 - diagnosis; D-dimer; D-dimer to lymphocyte ratio; Fibrin Fibrinogen Degradation Products; Humans; immunothrombosis; lymphocyte; Lymphocytes; mortality; Neutrophils; Retrospective Studies; COVID-19; D-dimer; mortality; D-dimer to lymphocyte ratio; immunothrombosis; lymphocyte
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2022.1053039

Nowadays, there is still no effective treatment developed for COVID-19, and early identification and supportive therapies are essential in reducing the morbidity and mortality of COVID-19. This is the first study to evaluate D-dimer to lymphocyte ratio (DLR) as a prognostic utility in patients with COVID-19. We retrospectively analyzed 611 patients and separated them into groups of survivors and non-survivors. The area under the curve (AUC) of various predictors integrated into the prognosis of COVID-19 was compared using the receiver operating characteristic (ROC) curve. In order to ascertain the interaction between DLR and survival in COVID-19 patients, the Kaplan-Meier (KM) curve was chosen. Age ( = 1.053; 95% , 1.022-1.086; = 0.001), NLR ( = 1.045; 95% , 1.001-1.091; = 0.046), CRP ( = 1.010; 95% , 1.005-1.016; < 0.001), PT ( = 1.184; 95% , 1.018-1.377; = 0.029), and DLR ( = 1.048; 95% , 1.018-1.078; = 0.001) were the independent risk factors related with the mortality of COVID-19. DLR had the highest predictive value for COVID-19 mortality with the AUC of 0.924. Patients' survival was lower when compared to those with lower DLR (Log Rank 0.001). DLR might indicate a risk factor in the mortality of patients with COVID-19.